homepage  accelmed vision  strategy  team  portfolio  contact    accelmed invests in private and public medical device companies around the world accelmed merges global businesses with promising medical device startups creating significant revenue growth accelmed’s platform model has proven to provide high returns to investors managers and entrepreneurs accelmed invests in private and public medical device companies around the world accelmed merges global businesses with promising medical device startups creating significant revenue growth accelmed’s platform model has proven to provide high returns to investors managers and entrepreneurs accelmed invests in private and public medical device companies around the world accelmed merges global businesses with promising medical device startups creating significant revenue growth accelmed’s platform model has proven to provide high returns to investors managers and entrepreneurs             merging medtech innovation with global commercial platforms    accelmed is an investment firm focused on value creation for medical device companies and technologies accelmed was founded in  by mori arkin and uri geiger and invests in small and midcap private and public companies with its proven track record and large team of accomplished investment professionals accelmed’s vision is to create leading medtech players by merging commercial platforms with small innovative growth companies predominantly from israel                       integrating commercial platforms with innovation and providing growth equity to foster significant value creation   accelmed brings its acumen in medical devices and its dominant presence in israel to the platform model which has already been implemented with great success under the platform model accelmed integrates innovative and marketready medical device technologies into existing commercial companies that are able to effectively distribute and commercialize the new products accelmed makes significant equity investments – or a combination of equity and debt – of between m and m per platform in certain cases in combination with its coinvesting partners investment can be increased to up to m we intend to acquire a significant interest in established medical device companies in the us europe and potentially in china with revenues in excess of m and which have an experienced direct sales force     proceeds of our investments will be used for both organic and inorganic growth through the acquisition and integration of innovative market ready medical device technologies identified and selected by accelmed and the platform company management the acquired israeli startups will serve as ongoing sources for costefficient rd as based on accelmed’s proven experience with israeli rd teams  they are not only innovative but also operate in a faster and more efficient way than their peers overseas     platform case studies endochoice – platform model case study the platform model modus operandi is best illustrated through the merger between peer medical an israeli company and developer of the full spectrum endoscope and endochoice a gastroenterology gi player in atlanta ga which had a solid commercial infrastructure but which lacked innovative products by merging peer into endochoice and the addition of working capital accelmed was able to transform endochoice from a commodity player into a cutting edge technology company the merger carried out in  led to endochoice’s emergence as a leading global gi player with sales above m in  more than doubled since the merger high doubledigit growth and a presence in more than  countries endochoice completed a successful ipo on june  and was sold to boston scientific in october          ois – platform model case study ois is another example of the successful deployment of accelmed’s platform model ois a californiabased ophthalmic imaging systems player acquired medivision the developer of an innovative retinal camera based on israeli defense technology the deal was financed and led by accelmed which held  of ois’s shares postmerger in  within two years ois was sold providing accelmed with an outstanding return                       team  mori arkin cofounder and chairman of the investment committee   mori arkin is one of israel’s most successful life science entrepreneurs he was the principal shareholder and chairman of agis industries  ltd from its establishment until its merger with perrigo in  agis one of the leading generic pharmaceutical companies in israel merged with usbased perrigo in march  in an  million transaction mr arkin has a degree in psychology and philosophy from the tel aviv university  dr uri geiger cofounder and managing partner   uri geiger brings extensive entrepreneurial management and investment knowhow having created and built many successful medical device enterprises until january  dr geiger served as ceo of exalenz bioscience ltd taseexen developer of an innovative breathbased technology for diagnosing liver and gastrointestinal disorders that was acquired from oridion systems today part of covidien and dr geiger took public in  he previously cofounded and was the ceo of galayor networks a developer of optical components sold in  to memscap euronext mems dr geiger is also the founding partner of dragon variation fund one of israel’s first hedge funds which was sold to migdal in  dr geiger worked on wall street during the s where he gained a broad understanding of capital markets and significant experience which he put to use after returning to israel in  dr geiger was formerly an adjunct professor at the recanati business school at tel aviv university where he lectured on private equity and venture capital he is the author of the books startup companies and venture capital tel aviv university press  and from concept to wall street financial times – prentice hall  he earned his doctorate from new york’s columbia university center for law  economics where he majored in global equity markets dr geiger served as a major in the israeli air force  dr irit yaniv md mba general partner   irit yaniv is an experienced and accomplished senior executive in the medtech industry and has held ceo positions with medical device companies impulse dynamics and metacure she plays an important role in leading accelmed’s early stage portfolio companies serving either as chairperson or as an active board member dr yaniv holds an md degree from the bengurion university and an mba from the recanati business school at tel aviv university  ilan ben oren partner  cto   mr ben oren brings more than  years’ experience in rd and management in the medical equipment field  mr ben oren assists accelmed’s portfolio companies in various development tasks prior to joining accelmed he served as the cto of exalenz bioscience ltd taseexen a developer of an innovative breathbased technology for diagnosing liver and gastrointestinal disorders prior to that mr ben oren held various positions from project manager to cto at oridion medical swxoridn earlier in his career he worked as a senior physicist at scitex ltd nasdaqscix and participated for five years in applied research at the laser center of hadassah hospital einkerem and the hebrew university mr ben oren is the author of more than  patents and patent applications in the field of medical technologies and electrooptics he holds a master’s degree in applied physics and the science of materials summa cum laude from the hebrew university of jerusalem  amir blatt partner   amir blatt brings wide experience in both the investment and medical device fields prior to joining accelmed mr blatt was an analyst at goren capital group advising investors ta companies and the government of israel on ma activity previously mr blatt held several sales and marketing positions with dover medical devices the jj distributor of diagnostics equipment in israel mr blatt graduated as a biotechnology engineer from the technionisrael institute of technology in haifa and holds an mba from the recanati school of management at tel aviv university  dr guy ohad chief medical officer   dr guy ohad is a radiologist with rich experience in the field of technology and medical devices his most recent positions include ceo at pop medical solutions a woman’s health company developing a minimal invasive device for treatment of pelvic organ prolapse before this he was vp of clinical and business development of the cr product line at orex a csh company former kodak in addition he served as a consultant to several medical device companies and served as clinical advisor at medica vc dr ohad holds a md from tel aviv university  dr susan alpert md phd chief regulatory officer   susan alpert formerly chief regulatory officer of medtronic is accelmed’s senior regulatory and clinical advisor she provides services to accelmed on a part time  basis working with accelmed portfolio companies as well as assisting accelmed in reviewing and evaluating investment opportunities dr alpert has held the positions of senior vice president and chief regulatory officer at medtronic until  and had a similar role at cr bard nysebcr before joining medtronic she held a number of positions with the fda including as director of the fda’s office of device evaluation dr alpert holds md and phd in infectious diseases from the nyc school of medicine   nadav shimoni associate   madav shimoni completed his medical studies at the ben gurion university bgu of the negev in beer sheva mr shimoni previously served as a project manager at an idf elite technological unit gaining significant experience in developing and designing complex mechanical elements in addition he is an anatomy teaching assistant at the medical school for international health msih – a collaboration between bgu and columbia university medical center he also engages in active volunteering work including medical workshops for populations in need  nir gilad analyst   nir gilad is involved with investment analysis and ongoing portfolio management prior to accelmed mr gilad worked at the israeli ministry of defense as a project finance analyst leading the national project of relocating the idf’s units to the south of israel previously he served as a financial analyst at the idf’s elite technology unit leading the unit’s economic analysis awarded with an honor for excellence mr gilad is an associate mentor at the global business studies program at coller school of management at tel aviv university and he holds a ba in economics and an mba both from tel aviv university  dr gilad rotem analyst   dr rotem holds an md degree from the technionisrael institute of technology in haifa israel as well as a bsc from tel aviv university in industrial engineering and another in biology in addition mr rotem was formerly professional longdistance triathlete who has participated in numerous international competitions mr rotem’s strong academic background and accomplishments in professional sports give him a unique perspective on health and athletics making him a valued asset to the accelmed team   executives network accelmed enjoys close collaboration with a network of seasoned executives who have built led and sold companies for billions of dollars these executives assist accelmed in identifying and analyzing potential opportunities and may serve in key leadership roles in future platform companies             the portfolio reflects a diversity of strategies employed in accelmed’s first and second funds   platforms  cogentix   cogentix nasdaqcgnt is a us based global urology focused company its main areas of activity are in overactive bladder oab advanced endoscopy systems and urethral bulking agents  httpwwwcogentixmedicalcom    endochoice sold   a global platformtechnology company focused on gastrointestinal gi endoscopy endochoice has merged with peer medical an israeli company which developed of a unique endoscopy technology to form a leading player in the gi industry endochoice is headquartered in alpharetta georgia with its rd center based in israel endochoice completed a successful ipo in june  and was sold to boston scientific in october  httpwwwendochoicecom  ophthalmic imaging systems sold   ophthalmic imaging systems ois is a leading provider of ophthalmic imaging and informatics solutions ois was the first investment of accelmed closed q and was sold two years later q to merge healthcare nasdaq merge httpwwwcanadianpharmacynet” target”blank”httpwwwcanadianpharmacynet  volcano sold   through its multimodality platform volcano corporation nasdaq volc is the global leader in intravascular imaging for coronary peripheral and physiology applications accelmed took a role of an active investor in the company which contributed to a successful acquisition by philips only a few months later httpwwwvolcanocorpcom   targeted innovation  corvia   corvia is developing the first transcatheter device to treat congestive heart failure chf the company’s innovative iasd™ interatrial shunt device system is designed to relieve increased left atrial pressure httpcorviamedicalcom  valcare medical   valcare medical was founded in  and is dedicated to designing developing and commercializing devices and accessories for minimally invasive treatment of heart valve disease httpwwwvalcaremedicalcom  digma   digma medical is an exciting new medical device startup that is focused on developing innovative solutions to metabolic diseases  sonivie   sonivie is developing an advanced denervation solution to treat pulmonary hypertension   incubator  eximo medical   eximo medical ltd is an early stage startup company founded in  the company is developing a novel medical device based on a single use hybrid catheter for various medical applications that require precise and safe material removal these applications have substantial and growing markets httpwwweximomedicalcom  memic   memic innovative surgery ltd is an early stage robotic company that develops an innovative surgical robot the surgical robot is based on a novel design which enables intuitive control and a new surgical approach for laparoscopic procedures  nitinotes   nitinotes is developing advanced nonsurgical bariatric solutions  revamp   revamp is offering an innovative temporary catheter for acute heart failure ahf primarily targeting diuretic resistance patients   venture capital  cartiheal   cartiheal is the developer of proprietary biocompatible and biodegradable offtheshelf implants for cartilage and bone regeneration cartiheal’s acellular implant is arthroscopically pressfit within a cartilage or osteochondral defect in a singlestage procedure and supports vessels formation followed by rapid invasion and adhesion of bone marrow mesenchymal stem cells the ce marked implant has significant loadbearing capability allowing patients faster rehabilitation httpwwwcartihealcom  endospan   endospan ltd is a vcbacked clinicalstage medical device startup developing a novel endovascular system intended to provide the next generation in endovascular aortic aneurysm repair evar endospan’s system aims to achieve a much smaller crossing profile compared with contemporary devices the system is intended for unilateral and purely percutaneous approach thus simplifying and significantly shortening the procedure httpwwwendospancom  nitiloop   nitiloop is dedicated to the development of cutting edge vascular support microcatheters our technology provides superior operatorcontrolled positioning and support in multiple applications nitiloop brings to the market ‘first choice’ products to overcome difficult lesions httpwwwnitiloopcom  picardia   picardia ltd is a medical device startup company developing a novel low profile catheter for the treatment of aortic stenosis the company’s proprietary technology is based on delivering mechanical impact for creating fractures in valve calcifications without injuring the surrounding soft tissue this treatment which only takes several seconds is intended to increase the valve effective orifice area without the need to replace the valve httpwwwpicardiacom   contact us office  madison avenue suite b new york ny  tel  israel office  hachoshlim st th floor herzliya pituach  tel  email infoaccelmedcom   accelmed growth partners management ltd  ceo founder businessman  profile directorpedianet  list of ceos founders board members and company directors accelmed growth partners management ltd check out list of companies and businesses related to accelmed growth partners management ltd find out accelmed growth partners management ltd address and contact details view other people related to accelmed growth partners management ltd  coworkers colleagues companions etc address  hachochlim street th floor herzliya pituach  israel companies related to accelmed growth partners management ltd cikcompany namepositioncompany addresscogentix medical inc de feltl road minnetonka  accelmed growth partners management ltd on the web persons related to accelmed growth partners management ltd  cogentix medical inc denamepositioncityaccelmed growth partners agp ltdherzliya pituachaccelmed growth partners gp lpherzliya pituachaccelmed growth partners lpherzliya pituachdavid w andersondirector montgomeryvilledavid w andersondirector montgomerydavid w andersondirector orangeburgdavid w andersondirector montgomeryvillecynthia f ansaripresident and ceo orangeburgkenneth w ansteydirector natickkenneth w ansteydirector orangeburgkenneth w ansteydirector orangeburgkenneth w ansteyminneapoliscarlos babinifremontcarlos babinieastonwarren l bielkedirector eden prairiewarren l bielkedirector orangeburgwarren l bielkeinterim ceo eden prariepolsky bruceorangeburgyoav m cohenchief financial officer orangeburgjames a dortadirector minnetonkakeith j c darraghvice president finance orangeburganderson davidorangeburggerald d erbvp marketing  sales fishersuri geigerherzeliaron hadanichief executive officer teaneckron hadanichief executive officer teaneckron hadanichief executive officer orangeburgron hadaniteaneckdarin hammersceo minnetonkadavid hanukaorangeburgdavid hanukavp research and development orangeburggideon hirschmannorangeburggideon hirschmann orangeburggideon hirschmannvice president of operations orangeburggideon hirschmannorangeburgrydzewski johnorangeburgwolf katherineorangeburgoneda katsumiorangeburgrobert killchairman president and ceo minnetonkalothar koobdirector peabodylothar kooborangeburglothar koobdirector orangeburgmark s landmanvp operations medical segment sharonmark s landmanvp disposables operations orangeburgmark s landmanvice president pell lewisorangeburgkoob lotharorangeburgthomas m olmsteadvp sales medical segment university heightskatsumi onedachairman of bod alpinekatsumi onedadirector orangeburgkatsumi onedadirector jitendra patelvp sales industrial segment norwoodjitendra patelvp industrial division orangeburgjitendra patelvp sales industrial segment kenneth h paulusdirector minnetonkacheryl pegusdirector orangeburglewis c pelldirector naticklewis c pellvicechairman of bod orangeburglewis c pelldirector orangeburglewis c pelldirector natickbruce polskyorangeburgbruce polskydirector orangeburgbrett reynoldssvp cfo treasurer st paulkevin h rochedirector minnetonkajohn j rydzewskiorangeburgjohn j rydzewskidirector costa mesajohn j rydzewskidirector orangeburgkenneth a sametdirector rockvillenachum shamirdirector austingary siegelvp finance orangeburgkenneth a spectorvp rd framinghamjames p staunerdirector lake forestjames a tracycfo newtonuroplasty incminnetonkajohn j wallacedirector walthamjohn j wallacedirector walthamjohn j wallacedirector cantonjohn j wallacedirector orangeburgjohn j wallacebielke warrenorangeburgsven wehrweindirector minneapoliskatherine wolforangeburgkatherine wolfexec vp corp dev  cfo orangeburgkatherine wolfexec vp corp dev  cfo orangeburghoward i zaubermandirector orangeburg accelmed growth partners  pseps venture data skip to main content fundsventurefunds of fundsreal estatemezzaninebuyoutinfrastructuresecondariesperformance rankingsindustriesmanufacturingcomputer electronic and optical productsbatteriesmedical devicesmedical suppliespharmaceuticalsinformation servicesinvestorsseedseries aother ventureacquisitionsindividualsgrants accelmed growth partners industry  fund management isic code company type venture capital firm investing in medical device companies and technologies overview  pseps web site httpwwwaccelmedcom funds managed fund fund type vintage ccy committed capital accelmed growth partners lp usd  add a funding round or a fund closing add an employee pseps id external links search form search more like this accelmed growth partners lp capman russia ii fund thomas weisel global growth partners aligned partners apis partners llp horizon capital advisors llc trivest partners lp investment themes funds d printing advanced materials artificial intelligence augmented and virtual reality ar vr automotive blockchain cybersecurity drones  uavs education electric vehicles energy harvesting energy storage fintech internet of things iot nanotechnology robotics sensors wearable technology user login username  password  create new account request new password navigation stock exchanges terms of use  copyright  by pseps ltd all rights reserved eximo medical an accelmed portfolio company announces the successful completion of a multi center first in human trial in europe with a hybrid catheter employer login post jobs job seeker login sign up search life sciences jobs search job title only radius miles km  news  news by subject  news by disease   news by date  search news get our freeindustry enewsletter email       eximo medical an accelmed portfolio company announces the successful completion of a multicenter firstinhuman trial in europe with a hybrid catheter for treating complex lesions in peripheral blood vessels tweet   am   life sciences jobs     bullet newest jobs  last  hours   bullet california jobs   bullet massachusetts jobs   bullet new jersey jobs   bullet maryland jobs   bullet washington jobs   view more jobs next generation novel hybrid laser  mechanical system provides a safe solution for more than  million patients in the united states  a market of over  billion rehovot israel april   prnewswire  eximo medical a medical device company that is developing a laser system and unique catheters for the treatment of peripheral artery disease pad has successfully completed a multicenter clinical trial for the purpose of obtaining ce approval for marketing in europe the results of the trial indicate that use of the eximo system provides a safe precise and highly efficacious solution in cases of partial blockage complete blockage and severe calcification the trial which was led by two physicians from poland included  patients some of whom required bypass surgery or leg amputation and are no longer at risk of amputation following the treatment eximo was founded by accelmed a medical device investment fund in  in july  eximo completed its round a investment led by accelmed following the success of the trial the company is now pursuing ce mark and will be looking to receive fda approval in  the eximo system is based on a solidstate ultraviolet laser with a wavelength of  nm the system is connected to a hybrid catheter which combines tissue ablation by means of the laser and resection with a blunt mechanical blade eximo is the first company in the world to have succeeded in actively combining a  nm laser with a mechanical blade in a way that enables a high level of accuracy in cutting through vascular blockages eximos proprietary hybrid lasermechanical blade design removes blockages irrespective of the type of blockage or the size of the blood vessel and increases the efficacy and safety of performance while reducing the risk of puncturing the blood vessel compared to competing technologies vascular blockage of the lower extremities is the main cause of  of limb amputations in the united states approximately  amputations per year with an estimated total cost of  billion to the us health system treatment with the system developed by eximo will enable the blockage to be efficiently and safely eliminated saving many patients from limb amputations today there are over  million pad patients in the united states and the market size is estimated to be in excess of  billion dr waclaw kuczmik senior surgeon at the medical university of silesia in katowice poland stated we are proud to be the first medical center in the world to have treated patients with the eximo system the treatment of all  patients by us was highly successful without any complications all of the patients have experienced significant pain relief in the treated limb and significant improvement in quality of life yoel zabar ceo of eximo stated we are pleased to announce the successful completion of a firstinhuman study with a pad application which constitutes a significant milestone that will enable the receipt of ce marketing approval in europe we are proud that thanks to the unique technology developed by our company we were able to alleviate patients suffering and prevent complicated unnecessary surgeries which could in extreme cases even have led to amputation of the leg the completion of the trial represents an additional significant step toward a multiparticipant fda trial in the united states  a potential market of billions of dollars about eximo eximo medical ltd which is located in rehovot is an israeli company that was founded in  by accelmed the company is devoted to developing efficacious and safe solutions for the treatment of vascular blockages the companys catheters are based on an innovative hybrid technology which includes a combination of a compact laser system and mechanical elements eximos future products include solutions for the removal of pacemaker electrodes le  lead extraction in cases of damage to the electrode or infection and at a later stage catheters for procedures in the digestive tract in march  eximo won the innovative company award at the idss electrophysiology conference the founders of the company and a scientific consulting committee which includes renowned specialists from american and israeli medical institutes support the eximo medical management team additional information is available on the companys website httpwwweximomedicalcom about accelmed accelmed is the largest pure play medical device fund in israel accelmed focuses on global investments in mature companies that might serve as a platform to israeli companies and also builds companies that develop innovative medical devices solutions for major markets  such as diabetes obesity and heart diseases  in which there is currently no medical solution since it was founded in  by mori arkin the chairman of the investment committee and dr uri geiger the managing partner accelmed has made  investments in medical device companies including ma and ipo of five of them accelmed manages over  million invested in medical device and has recently announced initial closing for its third fund accelmed growth partners  agp existing companies in the portfolio include corvia valcare endospan sonivie cartiheal nitiloop digma memic and nitinotes accelmed has a large and experienced investment management team which other than dr uri geiger and mori arkin includes four additional partners dr irit yaniv ilan ben oren lior shav and amir blatt together with a team of analysts and wellknown advisors more information can be found on accelmeds website httpwwwaccelmedcom for more information meirav bauer km investor relations ltd tel  meiravbkmircoil httpwwwkmircoil read at biospacecom related news  awesome biotechs to know in paris sec fines and bans once prominent bay area investor steven burrill over stolen investor funds genetically engineered pig hearts survive a recordbreaking two years inside baboons national heart lung and blood institute study spotlight on immigrant life science company leaders in massachusetts theranos hit again as new study shows firms tests arent as reliable as standard tests nonhormonal male birth control proves effective in early study university of illinois reveals dozens of startups are chasing the cancer blood test dream as flailing valeant vrx pushes back earnings deadlines bausch  lomb sale potentially on the table socal biotech trovagene trovs stock tanks after firing ceo cfo top talent leaving google googs verily googl after working with divisive and compulsive leader ceo andrew conrad please enable javascript to view the comments powered by disqus comments powered by disqus • biospacecom • eximo medical ltd   • medical devices • medical dev  diag  research                 valcare medical an accelmed portfolio company announces successful firstinhuman procedures of the amend™ catheter delivered annuloplasty ring  the business journals menu select a city national albany albuquerque atlanta austin baltimore birmingham boston buffalo charlotte chicago cincinnati columbus dallas dayton denver greensborowinstonsalem honolulu houston jacksonville kansas city los angeles louisville memphis miamifort lauderdale milwaukee minneapolisst paul nashville new york orlando philadelphia phoenix pittsburgh portland raleighdurham sacramento san antonio san francisco seattle silicon valley st louis tampa bay washington dc wichita limited time offer subscribe now search × close sign in sign in your account your account welcome your account sign in existing users create your free account dont have an account your account subscriptions newsletters custom notifications my custom site manage site users sign out sign in sign in your account search home industries  topics all industries  topics banking  financial services career  workplace commercial real estate education energy food  lifestyle government  regulations health care manufacturing media  marketing philanthropy  nonprofits professional services residential real estate retailing sports business technology transportation travel  tourism sponsored content cre now we value your business office environments small business marketing know your neighborhood news news latest news business pulse press releases lists  awards lists all lists build your own lists people  companies companies top private companies find businesses for sale search for company news people people on the move contact top executives executive profiles search for people in the news events events business event calendar nominations more… jobs find or post a job store subscriptions reprints  more how to grow your business advance your career thought leadership trends tips and insights from our partners subscribers manage your account about  contact about the business journals advertise help  faqs call center directory apps  syndication newsletters acbj publications bizwomen upstart hemmings sports business journal inside lacrosse bostinno dcinno chicagoinno austininno select a city national albany albuquerque atlanta austin baltimore birmingham boston buffalo charlotte chicago cincinnati columbus dallas dayton denver greensborowinstonsalem honolulu houston jacksonville kansas city los angeles louisville memphis miamifort lauderdale milwaukee minneapolisst paul nashville new york orlando philadelphia phoenix pittsburgh portland raleighdurham sacramento san antonio san francisco seattle silicon valley st louis tampa bay washington dc wichita follow us twitter linkedin facebook google  press releases valcare medical an accelmed portfolio company announces successful firstinhuman procedures of the amend™ catheter delivered annuloplasty ring jun   am edt herzliya israel june   prnewswire  novel semirigid d shaped ring provides a minimally invasive solution for mitral valve regurgitation  a market of over  billion in the us alone expands management team with appointment of mr shuki porath as ceo to lead clinical development and commercialization to current and new markets valcare medical an accelmed portfolio company the developer of novel medical devices for minimally invasive treatment of mitral valve regurgitation announced today the successful completion of first phase of the its firstinhuman fih multicenter clinical trial taking place in israel and europe valcare developed the amend™ mitral valve repair annuloplasty ring a semirigid a d shaped ring that emulates the current gold standard for patients who suffer from mitral valve regurgitation the valve that controls blood flow between the left atrium and left ventricle in a series of cases the ring was successfully trans apically delivered through an advanced catheterbased delivery system and was secured to the annulus by a series of novel integral anchors the procedure was performed on a high surgical risk patient in a minimallyinvasive transapical approach and in a relatively short time stated prof amit segev director cardiac catheterization services at the heart center at sheba medical center israel and prof ehud raanani head of the cardiothoracic surgery department who performed one of the procedures using the valcare system we were able to repair the patients mitral valve and significantly reduce valvular incompetence reducing mr from sever  to trace  we are excited to be one the first centers in the world to use this novel technology to help our patients additionally valcares amend™ system was implanted successfully by the heart team at shaare zedek medical center interventional cardiology laboratories in jerusalem dr almagor  dr mirkeen and in a compassionate care procedure performed in april by professor gino gerosa and dr andrea colli cardiac surgeons from the padova university hospital in italy alongside the clinical progress the company announced the expansion of its management team and the appointment of mr shuki porath as ceo mr shuki porath has over  years of medical device senior managerial experience including product management business development commercialization and clinical applications prior to joining valcare medical mr porath served as president  ceo at keystone heart and as senior executive at biosense webster a johnson  johnson company mr porath holds a bsc in electrical engineering msc and mba  all from the technion israel institute of technology sam shaolian the founder of valcare and inventor of the technology will become the cto of the company and continue to lead the future products of the company uri geiger managing partner of accelmed and valcares chairman of the board commented we are excited with the successful completion of the first implantations of the amend™ system and thrilled to welcome shuki porath to valcare leading its clinical development and commercialization to current and new markets valcares novel technology is a pioneering breakthrough for the treatment of mitral valve regurgitation and could be a base for additional modalities for treatment of other valve disorders the team is currently focusing on adapting the delivery technique to a transeptal approach allowing for deployment of the system through a puncture in the groin as well as using the system to treat tricuspid incompetence another extremely common problem in addition we have explored this novel technology using the ring as a landing zone to support a mitral valve prosthesis in preclinical studies generating interest from a number of other companies active in this arena as this provides another opportunity to treat patients with conditions that may be more suitable for heart valve replacement than repair the amend™ system is expected to address the  billion market  billion in the us alone for medical devices geared towards minimally invasive treatment of mitral valve disease a recently granted us patent on the valve in ring enables valcare to use the amend™ device also for the replacement of the mitral valve and for tricuspid vale repair about valcare medical  valcare medical based in herzliya pituach israel develops advanced medical implants and delivery systems for the treatment of heart valve regurgitation in a minimally invasive manner the valcare amend™ system is the first device aimed for treatment of mitral valve regurgitation and currently under clinical study by the company valcare medical was founded in  by accelmed fund as part of its targeted innovation model accelmed and valcare medicals founder and cto samuel shaolian established the company based on technology spanned off micardia corporation to leverage the expertise and experience of the leading technical and clinical experts in the field of heart surgery and cardiology to develop break though technologies for patients suffering from heart disease for more information refer to httpwwwvalcaremedicalcom about accelmed accelmed is the largest pure play medical device fund in israel accelmed focuses on global investments in mature companies that might serve as a platform to israeli companies and also builds companies that develop innovative medical device solutions for major markets  such as diabetes obesity and heart diseases  in which there is currently no medical solution since it was founded in  by mori arkin the chairman of the investment committee and dr uri geiger the managing partner accelmed has made  investments in medical device companies including ma and ipo of five of them accelmed manages over  million invested in medical device and has announced initial closing for its third fund accelmed growth partners  agp existing companies in the portfolio include corvia valcare endospan sonivie cartiheal nitiloop digma memic and nitinotes accelmed has a large and experienced investment management team in the medical device field which other than dr uri geiger and mori arkin includes four additional partners dr irit yaniv ilan ben oren lior shav and amir blatt together with a team of analysts and wellknown advisors more information can be found on accelmeds website httpwwwaccelmedcom for more information meirav bauer km investor relations tel  meiravbkmircoil httpwwwkmircoil source accelmed the information on this page is provided by pr newswire all rights reserved reproduction or redistribution of this content without prior written consent from pr newswire is strictly prohibited is not responsible for this content learn more about this service about pr newswire the information on this page is provided by pr newswire the business journals is not responsible for this content learn more eximo medical an accelmed portfolio company announces the successful completion of a multicenter eximo medical an accelmed portfolio company announces the successful completion of a multicenter firstinhuman trial in europe with a hybrid catheter for treating complex lesions in peripheral blood vessels next generation novel hybrid laser  mechanical system provides a safe solution for more than  million patients in the united states  a market of over  billion apr    et from accelmed rehovot israel april   prnewswire  eximo medical a medical device company that is developing a laser system and unique catheters for the treatment of peripheral artery disease pad has successfully completed a multicenter clinical trial for the purpose of obtaining ce approval for marketing in europe the results of the trial indicate that use of the eximo system provides a safe precise and highly efficacious solution in cases of partial blockage complete blockage and severe calcification the trial which was led by two physicians from poland included  patients some of whom required bypass surgery or leg amputation and are no longer at risk of amputation following the treatment eximo was founded by accelmed a medical device investment fund in  in july  eximo completed its round a investment led by accelmed following the success of the trial the company is now pursuing ce mark and will be looking to receive fda approval in  the eximo system is based on a solidstate ultraviolet laser with a wavelength of  nm the system is connected to a hybrid catheter which combines tissue ablation by means of the laser and resection with a blunt mechanical blade eximo is the first company in the world to have succeeded in actively combining a  nm laser with a mechanical blade in a way that enables a high level of accuracy in cutting through vascular blockages eximos proprietary hybrid lasermechanical blade design removes blockages irrespective of the type of blockage or the size of the blood vessel and increases the efficacy and safety of performance while reducing the risk of puncturing the blood vessel compared to competing technologies vascular blockage of the lower extremities is the main cause of  of limb amputations in the united states approximately  amputations per year with an estimated total cost of  billion to the us health system treatment with the system developed by eximo will enable the blockage to be efficiently and safely eliminated saving many patients from limb amputations today there are over  million pad patients in the united states and the market size is estimated to be in excess of  billion dr waclaw kuczmik senior surgeon at the medical university of silesia in katowice poland stated we are proud to be the first medical center in the world to have treated patients with the eximo system the treatment of all  patients by us was highly successful without any complications all of the patients have experienced significant pain relief in the treated limb and significant improvement in quality of life yoel zabar ceo of eximo stated we are pleased to announce the successful completion of a firstinhuman study with a pad application which constitutes a significant milestone that will enable the receipt of ce marketing approval in europe we are proud that thanks to the unique technology developed by our company we were able to alleviate patients suffering and prevent complicated unnecessary surgeries which could in extreme cases even have led to amputation of the leg the completion of the trial represents an additional significant step toward a multiparticipant fda trial in the united states  a potential market of billions of dollars about eximo  eximo medical ltd which is located in rehovot is an israeli company that was founded in  by accelmed the company is devoted to developing efficacious and safe solutions for the treatment of vascular blockages the companys catheters are based on an innovative hybrid technology which includes a combination of a compact laser system and mechanical elements eximos future products include solutions for the removal of pacemaker electrodes le  lead extraction in cases of damage to the electrode or infection and at a later stage catheters for procedures in the digestive tract in march  eximo won the innovative company award at the idss electrophysiology conference the founders of the company and a scientific consulting committee which includes renowned specialists from american and israeli medical institutes support the eximo medical management team additional information is available on the companys website httpwwweximomedicalcom about accelmed accelmed is the largest pure play medical device fund in israel accelmed focuses on global investments in mature companies that might serve as a platform to israeli companies and also builds companies that develop innovative medical devices solutions for major markets  such as diabetes obesity and heart diseases  in which there is currently no medical solution since it was founded in  by mori arkin the chairman of the investment committee and dr uri geiger the managing partner accelmed has made  investments in medical device companies including ma and ipo of five of them accelmed manages over  million invested in medical device and has recently announced initial closing for its third fund accelmed growth partners  agp existing companies in the portfolio include corvia valcare endospan sonivie cartiheal nitiloop digma memic and nitinotes accelmed has a large and experienced investment management team which other than dr uri geiger and mori arkin includes four additional partners dr irit yaniv ilan ben oren lior shav and amir blatt together with a team of analysts and wellknown advisors more information can be found on accelmeds website httpwwwaccelmedcom for more information   meirav bauer km investor relations ltd tel  meiravbkmircoil httpwwwkmircoil source accelmed view table fullscreen view table fullscreen journalists and bloggers the news you need when you need it join pr newswire for journalists to access all of the free services designated to make your job easier in need of subject matter experts for your story submit a free profnet request and find the sources you need learn more jun    et preview valcare medical an accelmed portfolio company announces successful firstinhuman procedures of the amend™ catheter delivered annuloplasty ring mar    et preview sonivie a portfolio company of accelmed fund announces successful completion of firstinhuman procedures using the tivus catheter my news release contains wide tables view fullscreen looking to send a news release with pr newswire take advantage of the worlds leading distribution platform sign up to get started request more information have an account log in search searching for your content advanced search cogentix medical grabs  million from accelmed employer login post jobs job seeker login sign up search life sciences jobs search job title only radius miles km  news  news by subject  news by disease   news by date  search news get our freeindustry enewsletter email       cogentix medical grabs  million from accelmed tweet   am   life sciences jobs     bullet newest jobs  last  hours   bullet california jobs   bullet massachusetts jobs   bullet new jersey jobs   bullet maryland jobs   bullet washington jobs   view more jobs cogentix medical enters into definitive agreement for  million equity investment  proceeds to provide resources to execute urology focused business development strategy  proposed equity investment at  premium to market  all current outstanding debt to be converted into common shares minneapolis sept   prnewswire  cogentix medical inc nasdaq cgnt a medical device company that develops manufactures and markets innovative proprietary products for the urology market today announced that it has entered into a securities purchase agreement with accelmed growth partners lp  under the terms of the securities purchase agreement accelmed would purchase  million of cogentix medical common stock from the company at  per share a  premium over the closing price of the stock on september   and a premium of  over the average closing price over the last  days  the securities purchase agreement is subject to various closing conditions including approval by the shareholders of cogentix medical  accelmed is a premier capital resource for the medical device industry and is based in new york ny and hertzeliya israel  cogentix would apply the proceeds to working capital as well as the implementation of a business development strategy to acquire growth technologies addressing the urology marketas a condition to accelmed closing the equity investment the company will convert into common shares all the outstanding debt and accrued interest owed to lewis c pell one of the companys class i directors  cogentix currently owes a total of  million  million of principal and  million of accrued interest to mr pell  the company and mr pell have entered into a definitive agreement under which the debt owed by cogentix to mr pell will be converted into cogentix common stock at a price per share of  immediately prior to closing the accelmed securities purchase agreement  the agreement also provides that simultaneously with the conversion of such debt all outstanding warrants to purchase cogentix common stock that are held by mr pell will be cancelled the agreement with mr pell is subject to approval of the shareholders of cogentix medicalthe proposed transaction with accelmed has the ability to transform cogentix medical said darin hammers president and ceo of cogentix medical  while our team has been successfully executing our sales strategy and building our business in the urology market we have been resource constrained in terms of providing our sales organization with additional products to bring to our growing customer base  accelmed is one of the worlds leading private equity firms focused on the medical device industry and as israels largest medtech investor has a proven track record of integrating israeli technologies into established us medtech companies  accelmed believes the cogentix platform provides an excellent foundation from which to build a broad based leader providing innovative cost effective and clinically proven solutions to the growing urology marketplace  overall the proposed transactions significantly increase our cash resources eliminate all of our outstanding debt and dramatically improve our capital structure all at valuations that are  higher than what the market is currently awarding our companyupon closing of the proposed transactions there would be approximately  million shares of common stock outstanding of which mr pell would own approximately  and accelmed would own approximately   the current debt and accrued interest outstanding of  million would be eliminated and cogentix would have approximately  million of cash and marketable securities  in addition the terms of the proposed transaction call for accelmed to have the right to nominate two members to the cogentix medical board of directors which currently has six members  one of these directors would be uri geiger who will become chair of the cogentix board mr geiger cofounded accelmed in  and is currently a managing partner of accelmed mr geiger has extensive entrepreneurial management and investment expertise having created and developed many successful medical device companiesthe board of directors of cogentix medical established a special committee of the board comprised solely of independent directors to review these transactions and provide a recommendation to the full board  the special committee engaged duff  phelps llc to serve as its independent financial advisor and to provide an opinion in connection with the proposed transactions  the special committee retained duff  phelps based on duff  phelps qualifications reputation and experience in providing fairness opinions and its experience in valuing companies in the medical device industry duff  phelps has rendered its opinion that the financial terms of the proposed transactions taken as a whole are fair to the unaffiliated public stockholders of the company  the special committee recommended to the full board that it approve the transactions and the cogentix medical board of directors has unanimously approved the transactionswe have admired the revenue growth of cogentix medical under the leadership of darin and his team and believe that with the appropriate resources and a wellplanned business development strategy cogentix could expand into being one of the leaders in the urology marketplace said mr geiger  as a reflection of our confidence in the management team as well as the potential for the company we have agreed to make this investment at a premium to the current market price and look forward to working with the board and management to execute on a shared vision for cogentixadditional information about the transaction and where to find itthe proposed transactions will be submitted to the shareholders of cogentix medical for their approval  the shareholders will be asked to approve the securities purchase agreement and the issuance of shares to accelmed and mr pell in connection with that approval cogentix will file with the securities and exchange commission the sec a proxy statement containing information about the proposed transactions  shareholders are urged to read the proxy statement when it becomes available because it will contain important information  shareholders will be able to obtain a free copy of the proxy statement as well as other filings containing information about cogentix without charge at the secs website wwwsecgov or by calling sec  copies of the proxy statement and other filings with the sec can also be obtained without charge by directing a request to brett reynolds senior vice president and chief financial officer cogentix medical inc  feltl road minnetonka mn  this press release shall not constitute an offer to sell or the solicitation of an offer to buy the securities to be issued as a result of the proposed transactions  the securities to be issued in connection with the proposed transactions have not been registered under the securities act of  as amended or state securities laws and may not be offered or sold absent registration with the sec or an applicable exemption from such registration requirements participants in the solicitationcogentix and some or all of its directors and executive officers and other persons may be deemed to be participants in the solicitation of proxies from cogentix shareholders in respect of the proposed transactions  information regarding the directors and executive officers of cogentix is contained in the proxy statement for our  annual meeting of shareholders which was filed with the sec on april    additional information regarding the interests of such potential participants will also be included in the proxy statement when it becomes available about cogentix medicalcogentix medical inc headquartered in minnetonka minnesota with additional operations in new york massachusetts the netherlands and the united kingdom is a global medical device company  we design develop manufacture and market products for flexible endoscopy with our unique product lines featuring a streamlined visualization system and proprietary sterile disposable microbial barrier known as endosheath technology providing users with efficient and cost effective endoscope turnover while enhancing patient safety  we also commercialize the urgent® pc neuromodulation system an fdacleared device that delivers percutaneous tibial nerve stimulation ptns for the officebased treatment of overactive bladder oab  oab is a chronic condition that affects approximately  million us adults  the symptoms include urinary urgency frequency and urge incontinence  we also offer macroplastique® an injectable urethral bulking agent for the treatment of adult female stress urinary incontinence primarily due to intrinsic sphincter deficiency  for more information on cogentix medical and our products please visit us at wwwcogentixmedicalcom cgntg for further information cogentix medical inc brett reynolds svp and cfoevc group doug sherkbrian moore investorscautionary statements related to forwardlooking statementsthis press release includes forwardlooking statements  these forwardlooking statements generally can be identified by the use of words such as anticipate expect plan could may will believe estimate forecast goal project and other words of similar meaning  forwardlooking statements in this press release include but are not limited to statements about the benefits of the proposed transactions expected levels of continuing debt expected revenue growth rates the anticipated timing of cash flow breakeven from operations and cash flow positive from operations and our plans objectives expectations and intentions with respect to future operations products and services  each forwardlooking statement contained in this press release is subject to risks and uncertainties that could cause actual results to differ materially from those expressed or implied by such statement  applicable risks and uncertainties include among others the effects of industry economic or political conditions outside of our control the failure to appropriately apply the proceeds from the proposed transactions or to realize the benefits of the reduction in our debt or delay in realization thereof operating costs and business disruption following completion of the transaction transaction and related costs actual or contingent liabilities the adequacy of our capital resources and the risks identified under the heading risk factors in the annual report on form k for the fiscal year ended march   filed with the sec on june   our transition report on form k for the transition period from april   through december   as well as our subsequent quarterly reports on form q and other information filed by us with the sec  we caution investors not to place considerable reliance on the forwardlooking statements contained in this presentation  you are encouraged to read our filings with the sec available at wwwsecgov for a discussion of these and other risks and uncertainties the forwardlooking statements in this presentation speak only as of the date of this release and we undertake no obligation to update or revise any of these statements  our business is subject to substantial risks and uncertainties including those referenced above  investors potential investors and others should give careful consideration to these risks and uncertainties to view the original version on pr newswire visithttpwwwprnewswirecomnewsreleasescogentixmedicalentersintodefinitiveagreementformillionequityinvestmenthtmlsource cogentix medical inc read at biospacecom related news healthcare industry leader kenneth a samet joins cogentix medical board of directors investors wait patiently for gilead gild and its ceo to make a ma for growth and to get out of share slump cogentix medical to change fiscal year mylan myl rebuffs rumors ceo will step down cogentix medical names former uroplasty upi exec as new ceo neurophage transforms into proclara bags  million and and launches phase ib alzheimer’s trial cogentix medical reports fourth quarter and full year fiscal  results parexel prxl loses  million in value in one day after disclosing possible misappropriation of corporate funds cogentix medical reports  percent q revenue growth how gilead gild can make another  billion every year please enable javascript to view the comments powered by disqus comments powered by disqus • biospacecom • cogentix medical   • biotechpharma  finance • medical devices • medical dev  diag  finance                 valcare medical an accelmed portfolio company announces successful firstinhuman procedures of the amend™ catheter delivered annuloplasty ring  news press release  pharmiwebcom navigation accesskey  content accesskey  site search accesskey  job seekers login accesskey  top of page accesskey  go to pharmiweb solutions login  register select a companyabbott diabetes careabbott laboratoriesaccelsiorsaccord healthcareaci group ltd  allchem pharmaactelion pharmaceuticals ltdad instrumentsadallen pharmaadamas consultingaddex pharmaceuticals adds advanced drug development servicesadecco group uk  irelandadelphi groupadvance recruitmentadvanced clinical recruitment ltdadvanced medical solutionsadvanced regulatory uk  europeadvanced ss medical  clinicaladvanced ss usaaerotek allegis group ltdaesica pharmaceuticals limitedaffinity group limitedaffinity group limitedagenda resource managementajilon pharmaakos ltdaktor interactivealconalexander mann servicesalimera sciences limitedallander noble limitedallergan incallergy therapeutics ltdallianz worldwide carealmacalnylam pharmaceuticalsalto marketing limitedaltranamarisamoria bondanglo technical recruitmentanthony nolanantisoma research laboratories ao foundationapex international recruitment ltdapplied driving techniquesaqdotsarcher mathiesonarchimedes pharmaargyll scottarmstrong craven ltdasa medicalashfield healthcare communicationsashfield infocus ltdaspen globalaspire resourcing ltdaspirion pharmaassociation for clinical data managementassociation of clinical research professionalsassociation of clinical research professionalsastbury marsdenastellas qaastralisastrazenecaastrazenecaastrazenecaastrazeneca commercialatom recruitmentaustin fraser limitedaverion international switzerland ltdaverion international corpaxessaxon neuroscience crm services sebaron crawford searchbarrington james clinicalbarrington james europebarrington james medical  executivebarrington james scientificbarts  the london school of medicine  dentistrybarts and the london nhs trustbarts health nhs trustbasecasebausch  lombbayerbayer plcbbi groupbdberesford blake thomasberwick partnersbicycle therapeutics limitedbio products laboratorybio products laboratory limitedbiokinetic europe ltdbioclinicabioenvision ltdbiogen idecbiogen idec international gmbhbiomarin europe limitedbiomedical systemsbiomedical systemsbiorole scientific solutionsbiotronik agbioviabioxydynbiz recruitmentblue pelican pharmabluewavebmj groupbms sales specialists llpboc gases  uk microcylindersboehringer ingelheim schweiz gmbhboehringer ingelheim gmbhboehringer ingelheim pharma gmbh  co kgbootsbounty uk limitedboyden francebreast cancer nowbrecon pharmaceuticals ltdbridgehead internationalbristol myers squibbbritish biocell bth recruitmentbusiness swedencc group holdings ltdcalderdale  huddersfield nhs foundation trustcalderdale and huddersfield nhs foundation trustcaleacambridge regulatory services ltdcamris internationalcancer research ukcancer research uk  ucl cancer trials centre candour recruitmentcandy recruitmentcapita resourcingcardinal healthcardiome pharma corpcarl zeisscatalent pharma solutionscatalent pharma solutionscatenoncatenon iberia saucca  limitedccibccm healthcare ltd ukcdc solutionscelgene international sarlcelgene ltdcelltechcenduitcentre for international migration and developmentchameleon international search ltdcharles river laboratoriescharterhousechasechilternchironchiron vaccinescircassia limitedcircassia pharmaceuticalscis life sciencescititec associates limitedcity of london group plcck clinicalclark james limitedclay mcguireclearwater people solutionsclinical network services pty ltdclinical professionals ltdclinical trials victoria limitedclinipace worldwide was paragon biomedicalclinipace worldwide was paragon biomedicalclinipace worldwide was paragon biomedicalclinphoneclinsys clinical researchclinteccloud nine recruitment solutions ltdcluepoints sacmed group ltdcognitive drug research ltdcognitive drug research ltdcognizant technology solutions uk ltdcognolink ltd cogstate ltdconcordiaconstares gmbhcontact singaporecorbioncordiscorelab partners inccovancecplcpl recruitment  science  cpl resources plccrccrf health management ltdcriticaltalent limitedcrofessionals llccromedicacromsourcecromsourcecslcsl behringcsl limitedcsl limited csl limitedcsl recruitmentctc resourcing solutionscti clinical trial and consulting servicescti clinical trial and consulting servicescurium pharmacustom clinical solutionscustom interconnect ltdcyteldabur oncologydaiichi sankyodaiichi sankyo uk ltddanisco sweeteners oy  dupont nutrition  healthdanonedatamonitordatatrial ltddcz life science personalmanagement gmbhddr jobsde verchin  partnersdecision resources international incdecode geneticsdefence science and technology laboratorydelphic diagnosticsderks  derks bvdermal laboratoriesdevrodiamond light source ltddignity sciencesdndidndidocs globaldocs global continental europedokumedsdolon ltddr reddysdrug safety peopleeamesjonesjudgehawkingseasthornebsco publishingedelway switzerland ageden scottedqmedqm council of europeef medicaleirx therapeutics ltdeisai europe ltdeisai london research laboratories limitedelaine coyleelan computing schweiz agelan itelevate direct ltdeli lillyeli lillyeli lilly and companyeli lilly and company ltdeli lilly contractsemsearch search and selectionendpoint research enhance people consultantsenhancing ltdentrust resourcing solutionsenvalisenvigoepm scientificeprofile pharma consultants sarlergon resourcesesiftethical medicines industry groupeupraxia pharmaceuticals inceuromedicaeuropean clinical research infrastructure networkeuropean patent officeeuropitaleuropital eusa pharmaevaluatepharma ltdevidenciaevideraevolution consultantsevolve selectionevotecewi recruitmentexcel communicationsexcellion bvexcelya sasexecutives onlineexemplar peopleexemplar peopleexperisf hoffmannla roche agfacilitate ltdfagron uk ltdfal duivenbvfarillonfforde managementfideltafindfindersfisher clinicalflame pharmafood standards agencyfr europefrazer jonesfreedom life sciencesfresenius kabifresenius kabifulcrum pharmafulcrum pharma europe ltdfulcrum pharma europe ltdfutures clinicalfutures executivefutures resourcingfutures salesfuturestep uk ltdgalderma uk ltdgalderma rdgalloway jones consultinggalpharm internationalgavi alliancegce solutionsgenea biomedxgenentechgenentechgenericsweb ltdgenmab ltdgenomic healthgenomics englandgenzyme ltdgenzyme therapeuticsgeorge clinicalgerd schierenberg search  selection gmbhgerson lehrman groupgetingegfk bridgeheadgilead sciencesglaxosmithklineglaxosmithkline plcglenmark generics europe ltdglenmark pharmaceuticalsglenmark pharmaceuticals saglobe life sciencesglycotope gmbhgold groupgrafton recruitmentgreen park contentgreythorngrunenthal ltdgskgskgw pharmaceuticalsgw pharmaceuticalsgw pharmaceuticals plchal allergy grouphales and hindmarsh associates ltdhammersmith medicines research ltdharvey nash aghayburyhays bvhays healthcare hays life scienceshc solutions uk ltdhealth decisionshealthcare at homehealthcare communications associationhealthcare technology internationalheronhmg worldwidehobson priorhodes healthcarehoggett bowershollister limitedhospira adelaide pty ltdhospira uk ltdhr dynamics hudsonhudson shribman scientific recruitmenthumanicshumanvaluehunter macdonald ltdhuntingdon life sciences ltdhuntress grouphvivo plchypha discovery ltdipharm consultingibcsg international breast cancer study groupicardiac technologies incicon clinical researchicon development solutions icon plcicrg ltdid search  selectionidisidox tfplids ukiir conferencesimanova ltdimmucorimmunocore ltdimmunodiagnostic systemsimperial college londonimperial college londonimperial college londonims healthinc researchincrom europeindex pharmaceuticalindigomedicalinharmony gmbh innopharma srlinnovenninpharmation ltdinpharmation ltdinstitut jules bordet ijbinstitute for oneworld healthinstitute of cancer researchinstitute of clinical researchintercept pharmainternational centre for neurotherapeuticsintum ltdinventiv health clinicalinvivodata incirbm istituto di ricerche di biologia molecolare isis recruitment solutions ltditc pharmaiti life sciencesits pharmaixicojakob  partnersjanssen pharmaceuticajanssencilagjanssencilag ltdjcw life sciencesjobboxx executive searchjohnson  johnson medicaljohnson  johnson seincjoint clinical trials officekings college londonjuice resource solutionsjust pharmajust retirementkcr sakd consulting search  selectionkdc group kelly  king associates ltdkelly serviceskendlekendle internationalkenexakey people limitedkeyrus biopharmakienbaum executive consultantskienbaum executive consultantskienbaum executive searchkings health partners clinical trials officekings collegekingston general hospitalkirkham young ltdknow how recruitmentkoenigsteiner agenturkowa research europe ltdkubo recruitmentkuowa executive searchkyowa kirin international plclaser europe ltdlaser gmbhlaser grouplab supportlanglandlcg bioscienceleeds institute of health sciencesleica microsystems leiden university medical centre lfblife scanlife science consultants ltdlife science dynamicslife scientificlife technologieslifecycle marketing ltdlinde healthcare the linde group linical europe gmbhlinical spainliquentliverpool school of tropical medicinelloyds pharmacylongbridge international plclonza biologics plcludger ltdlupin europe limitedlymphoma associationmtagmalvern instrumentsmanagement forummanor executive searchmapi consultancymapi groupmapi valuesmarie stopes internationalmarix drug development limitedmarketplace technicalmarks sattinmartindale pharmamatchtech groupmatrix evidencemayne manufacturing solutionsmayne pharmamba intelligent solutionsmcguire global recruitment mci groupmdgroupmeadwestvacomediatum gmbhmedicines evaluation unitmedicines patent poolmedicor globalmedidata solutions incmedikidz limitedmedikidz ltdmedimmunemeditech mediameditech mediamedochemiemedochemie ltdmedpacemedpass international ltdmedscapemedsci healthcare communicationsmeetmerckmerck kgaamerck research laboratories italymerck serono sa  geneva merck serono ukmercuri urvalmercuri urval ltdmercury pharmamesmmhramichael page internationalmicromet ag mid cheshire hospitals nhs trustmiddleton jeffers recruitment ltdmikes test companymillward brown uk ltdmms holdings incmologen agmonitor monitoring force moorfields eye hospitalmoorfields pharmaceuticalsmoorfields pharmaceuticalsmorecambe bay hospitals nhs trustmorgan jonesmorgan keatingmorgan levymorgan philips executive searchmorgan prestwich pharmaceutical recruitmentmosaic regulatory solutionsmsdmsi group limitedmundipharma international limited mundipharma research ltdmurex biotech limitedmwv services austria gmghmylanmylan pharma uknamsanature communicationsnemaura pharmaneolab limitednestlé nestlé sanetwork jobsnetwork recruitmentnewcastle universitynhs blood  transplant  nhsbtnhs blood and transplantnhs innovations londonnicenicholas howardnorginenorth bristol nhs trustnorth point recruitmentnorthwest ehealthnovartisnovartisnovartis pharma agnovella clinical resourcingnovelle lynchnovo nordisk novo nordisknovocure gmbhnucleus centralnutricia limitednutricia ltdnuvisan clinical development solutions oldobsevaobvious solutions ltdochre houseocs consulting ltdoctodgers selectolea consultingoncall llconcore ukonline resourcingonly medics recruitment ltdono pharma uk ltdoptima searchoptimus search limitedoptuminsightoracle health sciencesorchard therapeuticsorganisation for the prohibition of chemical weapoorion clinical servicesortho biotechorthoclinical diagnosticsoryzon genomics otsuka frankfurt research institute gmbh outcomeoxford biomedica uk limitedoxford biomedica uk limitedoxford pharmagenesisoxford universityoxford university innovationoxitec limitedoxygen life science solutionspackaging coordinators incpage executivepanacea pharma projects ltdparexelparkacre enterprises ltdpathpatheon austria gmbh  co kgpdr partnerspenn pharmapeoplescoutpersoneelsadviesbureau goelenpfizerpfizer incpfizer nutrition ph associates ltdpharmolam internationalpharma consulting grouppharma marpharmadirect uk  europe ltdpharmaceutical  medical professionalspharmaceutical profilespharmalink consultingpharmalys ltdpharmareview ltdpharmarspharmasciencepharmaseekpharmiweb recruitmentpharmiweb solutionspharos ltdphilip chapper  company ltdphilip morris international management saphlexglobalphlexglobalpierrel research europe gmbhpierrel research europe gmbhplanet pharma staffing limitedplethora solutions limted plusprojectplymouth hospitals nhs trustpoise consulting ltdpop science limitedppdpra health sciencespreglempremier researchpricespective llcpricewaterhousecoopers llpprime pharmaprimevigilance primoris contract solutionsprma consulting ltdprn recruitmentproclinical ltdproductlife ltd formerly verius ltdprofessional careers consulting pcc ltdprogressive recruitmentprogressive recruitment germanypropagate propharma solutionsproscape technologiesprostrakan limitedprotexinpsi cro ltdpsi cro uk ltdpsi cro uk ltdpsr grouppsr group bvpsr pharma resourcepurinaqmaticquanticatequeen anne street medical centre quest resourcing ltdquintilesquintiles hungary ltd quintiles magyarország kftquotient bioresearchquotient clinicalquotient clinical ltdraftrainford berry limited random medical animationrayner intraocular lenses ltdrbw consultingrdl scientificreading scientific services ltdreal hr solutions real life sciencesreal life sciences germanyreal life sciences switzerlandreckitt benckiserrecruitmentrecruitment plusrecruitmentgeniusreed scientificregulatory professionalsregulis consultingrenovoresearch review recruitrespiratory effectiveness groupretrogenixrichmond pharmacologyrising tide gmbhrm it professional resources agrmgrnidrobarts clinical trials rocheroche diagnostics limitedroyal chemistry societyroyal free hospital hampsteadroyal liverpool  broadgreen university hospitalsroyal united hospital bathrpslrsa consulting gmbhrti health solutionsrushworth associates limitedruston poole intruston poole internationalscubed limitedsandoz biopharmaceuticalssankyo pharmasanofisb consultingscaschering health carescinopsissciprosck•censearch consultancysearch scientificsec recruitmentselborne biological services ltdselciaseltek consultantssentinelseqirus ltdseqirus ltdservierseven life sciencessharp clinical services uk ltdshire pharmaceuticalssiemens healthcare diagnosticssiemens medical solutions petnet solutionssigma aldrich corporationsigma recruitment ltdsigmar recruitment sp zoosignet resourcessimbec orion group ltdskills alliancesla pharma uk ltdsls servicessmerud medical research uk ltdsmith  nephew medicalsmith  nephew medical ltdsobisolvay healthcarespectrum regulatory solutionsspectrum regulatory solutions ltdspirax sarcospotted limited division jacobsen havelock woodspringer healthcare ltdsquare one pharmasquarepeg recruitment solutions ltdsra global clinical developmentsrg clinicalsrg interesourcesrl pharmaceuticalsssafast andrewsstamford consultantsstarstem med pte ltdsterling hr consultingsth nhs foundation truststhree management services ltdstiefel laboratories succinct healthcare communicationsswanstaff recruitment ltdswift selectionsymmetron ltdsynapse medical resourcing limitedsynarcsynarcsynarc incsynarc ltdsynchrogenix information strategies incsynchrogenix information strategies incsynergy visionsynexus limitedsynovate healthcaresynteracthcr deutschland gmbhsyreon corporationsyreon corporationsyreon corporationtakeda development centre europetalentmarktalentmark search  selectiontalisman software satardis medical consultancytaylor and francis grouptc biopharmtec group internationaltempleton recruitmentteva uk limitedtfs trial form support internationaltfs trial form support llctfs trial form support ltdthe christie nhs foundation the general pharmaceutical councilthe health protection agency hpa the institute of cancer researchthe leeds teaching hospitals nhs trustthe london clinicthe martin veasey partnershipthe medicines companythe nihr biomedical research centrethe rft groupthe science and technology facilities council the spencer groupthe spencer group ltdthe university of edinburgh theorem clinical researchtheorem clinical research was omnicaretheradex europe ltdthermo fisher scientificthermo scientific was remel europethirtythreethomson reutersthomson scientificthornshaw recruitmentthornton and ross limitedtmc pharma limitedtmp worldwidetower mains quality assurance tmqatpp recruitmenttransparency international uktrm oncology bvtrue north human capital ltdturner regulatoryubm medica ltduc davis health systemuc davis health systemucbuclunileverunited biosource corporationuniversity hospital bristoluniversity hospital of south manchesteruniversity of bristoluniversity of dundeeuniversity of durhamuniversity of hertfordshireuniversity of newcastle upon tyneuniversity of oxforduniversity of oxforduniversity of oxford  department of oncologyuniversity of sheffield university of southamptonuniversity of southampton clinical trials unituniversity of surreyuptodatevacancy management companyvalidantvantage recruitment solutions ltdvecturaveeda clinical research ltdvegenatvenn kinesisvenn life sciencesventana medical systemsverius ltdvertex pharmaceuticals europe limitedviiv healthcarevirdis groupvita green pharmaceutical hk ltdvoisin consulting life sciencesvrs regulatoryvsowacker chemie agwainwright associates limitedwebsearch recruitment ltdwentworth pharmaceuticalwhipps cross university hospital nhs trustwhitehall internationalwhitehead mannwilson alexander ltdwockhardt woodhurstworld class international wciworldwide clinical trialsworthing and southlands hospitals nhs trustx groupzeincro hellas sazest scientificzimmer biomet pharmiweb channelsall  pharmaco  clinical research  rdbiotech  salesmktg  healthcare  recruitment  pharmacy  medical comms home news show all pharmaco clinical research rd  biotech sales  mktg healthcare recruitment pharmacy medical comms resources pharmiweb today features press releases events job search handbook previous polls free personality test newsletter archive link directory editorial calendar company login events webinars courses other jobsearch job search executive jobs entry level pharma jobs auditor jobs biostatistics jobs brand manager jobs business development jobs clinical data manager jobs clinical project manager jobs cra jobs compliance jobs drug safety jobs feasibility jobs health economics jobs liaison jobs marketing jobs medical affairs jobs medical advisor jobs medical device sales jobs medical information jobs medical rep jobs medical writing jobs nurse  nursing jobs pharmaceutical marketing jobs pharmaceutical sales jobs pharmacist jobs pharmacovigilance jobs product manager jobs project management jobs qaqcquality jobs recruitment jobs regulatory jobs regulatory affairs jobs sales jobs sas programmer jobs statistics jobs study manager jobs companies show all pharmaco clinical research rdbiotech salesmktg healthcare recruitment pharmacy medical comms how to get a job using pharmiwebcom write a better cv write a covering letter get job as a medical sales rep give a leaving speech pass personality tests enter the cyberspace recruitment market cope with redundancy get past the receptionist get shadowing experience about us contact us jobs currently  jobs jobs in the uk jobs in europe jobs in usa jobs in asia global jobs candidates login sign in forgotten details cv database let the jobs come to you sign up company login account login open an account site newsletter sign up for the pharmiwebcom newsletter pharmiwebcom rss feeds pharmiweb candidate blog pharmiweb client blog pharmiweb on facebook advertising press release submit a press release send this to a friend go back to listvalcare medical an accelmed portfolio company announces successful firstinhuman procedures of the amend™ catheter delivered annuloplasty ringaccelmedposted on  jun more accelmed press releasespr newswire herzliya israel june   herzliya israel june   prnewswire  novel semirigid d shaped ring provides a minimally invasive solution for mitral valve regurgitation  a market of over  billion in the us alone expands management team with appointment of mr shuki porath as ceo to lead clinical development and commercialization to current and new markets valcare medical an accelmed portfolio company the developer of novel medical devices for minimally invasive treatment of mitral valve regurgitation announced today the successful completion of first phase of the its firstinhuman fih multicenter clinical trial taking place in israel and europe valcare developed the amend™ mitral valve repair annuloplasty ring a semirigid a d shaped ring that emulates the current gold standard for patients who suffer from mitral valve regurgitation the valve that controls blood flow between the left atrium and left ventricle in a series of cases the ring was successfully trans apically delivered through an advanced catheterbased delivery system and was secured to the annulus by a series of novel integral anchors the procedure was performed on a high surgical risk patient in a minimallyinvasive transapical approach and in a relatively short time stated profamit segevdirector cardiac catheterization services at the heart centerat sheba medical center israel and profehud raanani head of the cardiothoracic surgery departmentwho performed one of the procedures using the valcare system we were able to repair the patients mitral valve and significantly reduce valvular incompetence reducing mr from sever  to trace  we are excited to be one the first centers in the world to use this novel technology to help our patients additionally valcares amend™ system was implanted successfully by the heart team at shaare zedek medical center interventional cardiology laboratories in jerusalem dr almagor  dr mirkeen and in a compassionate care procedure performed in april by professor gino gerosa and dr andrea colli cardiac surgeons from the padova university hospital in italy alongside the clinical progress the company announced the expansion of its management team and the appointment of mr shuki porath as ceo mr shuki porath has over  years of medical device senior managerial experience including product management business development commercialization and clinical applications prior to joining valcare medical mr porath served as president  ceo at keystone heart and as senior executive at biosense webster a johnson  johnson company mr porath holds a bsc in electrical engineering msc and mba  all from the technion israel institute of technology sam shaolian the founder of valcare and inventor of the technology will become the cto of the company and continue to lead the future products of the company uri geiger managing partner of accelmed and val c are  s chairman of the board commented we are excited with the successful completion of the first implantations of the amend™ system and thrilled to welcome shuki porath to valcare leading its clinical development and commercialization to current and new markets valcares novel technology is a pioneering breakthrough for the treatment of mitral valve regurgitation and could be a base for additional modalities for treatment of other valve disorders the team is currently focusing on adapting the delivery technique to a transeptal approach allowing for deployment of the system through a puncture in the groin as well as using the system to treat tricuspid incompetence another extremely common problem in addition we have explored this novel technology using the ring as a landing zone to support a mitral valve prosthesis in preclinical studies generating interest from a number of other companies active in this arena as this provides another opportunity to treat patients with conditions that may be more suitable for heart valve replacement than repair the amend™ system is expected to address the  billion market  billion in the us alone for medical devices geared towards minimally invasive treatment of mitral valve disease a recently granted us patent on the valve in ring enables valcare to use the amend™ device also for the replacement of the mitral valve and for tricuspid vale repair about valcare medical  valcare medical based in herzliya pituach israel develops advanced medical implants and delivery systems for the treatment of heart valve regurgitation in a minimally invasive manner the valcare amend™ system is the first device aimed for treatment of mitral valve regurgitation and currently under clinical study by the company valcare medical was founded in  by accelmed fund as part of its targeted innovation model accelmed and valcare medicals founder and cto samuel shaolian established the company based on technology spanned off micardia corporation to leverage the expertise and experience of the leading technical and clinical experts in the field of heart surgery and cardiology to develop break though technologies for patients suffering from heart disease for more information refer to httpwwwvalcaremedicalcom about accelmed accelmed is the largest pure play medical device fund in israel accelmed focuses on global investments in mature companies that might serve as a platform to israeli companies and also builds companies that develop innovative medical device solutions for major markets  such as diabetes obesity and heart diseases  in which there is currently no medical solution since it was founded in  by mori arkin the chairman of the investment committee and dr uri geiger the managing partner accelmed has made  investments in medical device companies including ma and ipo of five of them accelmed manages over  million invested in medical device and has announced initial closing for its third fund accelmed growth partners  agp existing companies in the portfolio include corvia valcare endospan sonivie cartiheal nitiloop digma memic and nitinotes accelmed has a large and experienced investment management team in the medical device field which other than dr uri geiger and mori arkin includes four additional partners dr irit yaniv ilan ben oren lior shav and amir blatt together with a team of analysts and wellknown advisors more information can be found on accelmeds website httpwwwaccelmedcom for more information meirav bauer km investor relations tel meiravbkmircoilhttpwwwkmircoil source accelmed pr newswirewwwprnewswirecomlast updated on  subscribe in a reader send this to a friend key   required field your friends email your email enter your comment here if any human verification  advertising share    site map  privacy  security  cookies  terms and conditions pharmiwebcom is europes leading industrysponsored portal for the pharmaceutical sector providing the latest jobs news features and events listings the information provided on pharmiwebcom is designed to support not replace the relationship that exists between a patientsite visitor and hisher physician eximo medical an accelmed portfolio company announces the successful completion of a multicenter firstinhuman trial in e    toll free free membership login monitorquotechartstradesnewsfinancialstoplistsalertsportfoliolevel boards follow feedmost popularsitemapforex  futuresworld exchanges eximo medical an accelmed portfolio company announces the successful completion of a multicenter firstinhuman trial in e date    am source  pr newswire us eximo medical an accelmed portfolio company announces the successful completion of a multicenter firstinhuman trial in e tweet print rehovot israel april   prnewswire  eximo medical a medical device company that is developing a laser system and unique catheters for the treatment of peripheral artery disease pad has successfully completed a multicenter clinical trial for the purpose of obtaining ce approval for marketing in europe the results of the trial indicate that use of the eximo system provides a safe precise and highly efficacious solution in cases of partial blockage complete blockage and severe calcification the trial which was led by two physicians from poland included  patients some of whom required bypass surgery or leg amputation and are no longer at risk of amputation following the treatment eximo was founded by accelmed a medical device investment fund in  in july  eximo completed its round a investment led by accelmed following the success of the trial the company is now pursuing ce mark and will be looking to receive fda approval in  the eximo system is based on a solidstate ultraviolet laser with a wavelength of  nm the system is connected to a hybrid catheter which combines tissue ablation by means of the laser and resection with a blunt mechanical blade eximo is the first company in the world to have succeeded in actively combining a  nm laser with a mechanical blade in a way that enables a high level of accuracy in cutting through vascular blockages eximos proprietary hybrid lasermechanical blade design removes blockages irrespective of the type of blockage or the size of the blood vessel and increases the efficacy and safety of performance while reducing the risk of puncturing the blood vessel compared to competing technologies vascular blockage of the lower extremities is the main cause of  of limb amputations in the united states approximately  amputations per year with an estimated total cost of  billion to the us health system treatment with the system developed by eximo will enable the blockage to be efficiently and safely eliminated saving many patients from limb amputations today there are over  million pad patients in the united states and the market size is estimated to be in excess of  billion dr waclaw kuczmik senior surgeon at the medical university of silesia in katowice poland stated we are proud to be the first medical center in the world to have treated patients with the eximo system the treatment of all  patients by us was highly successful without any complications all of the patients have experienced significant pain relief in the treated limb and significant improvement in quality of life yoel zabar ceo of eximo stated we are pleased to announce the successful completion of a firstinhuman study with a pad application which constitutes a significant milestone that will enable the receipt of ce marketing approval in europe we are proud that thanks to the unique technology developed by our company we were able to alleviate patients suffering and prevent complicated unnecessary surgeries which could in extreme cases even have led to amputation of the leg the completion of the trial represents an additional significant step toward a multiparticipant fda trial in the united states  a potential market of billions of dollars about eximo  eximo medical ltd which is located in rehovot is an israeli company that was founded in  by accelmed the company is devoted to developing efficacious and safe solutions for the treatment of vascular blockages the companys catheters are based on an innovative hybrid technology which includes a combination of a compact laser system and mechanical elements eximos future products include solutions for the removal of pacemaker electrodes le  lead extraction in cases of damage to the electrode or infection and at a later stage catheters for procedures in the digestive tract in march  eximo won the innovative company award at the idss electrophysiology conference the founders of the company and a scientific consulting committee which includes renowned specialists from american and israeli medical institutes support the eximo medical management team additional information is available on the companys website httpwwweximomedicalcom about accelmed accelmed is the largest pure play medical device fund in israel accelmed focuses on global investments in mature companies that might serve as a platform to israeli companies and also builds companies that develop innovative medical devices solutions for major markets  such as diabetes obesity and heart diseases  in which there is currently no medical solution since it was founded in  by mori arkin the chairman of the investment committee and dr uri geiger the managing partner accelmed has made  investments in medical device companies including ma and ipo of five of them accelmed manages over  million invested in medical device and has recently announced initial closing for its third fund accelmed growth partners  agp existing companies in the portfolio include corvia valcare endospan sonivie cartiheal nitiloop digma memic and nitinotes accelmed has a large and experienced investment management team which other than dr uri geiger and mori arkin includes four additional partners dr irit yaniv ilan ben oren lior shav and amir blatt together with a team of analysts and wellknown advisors more information can be found on accelmeds website httpwwwaccelmedcom for more information   meirav bauer km investor relations ltd tel  meiravbkmircoil httpwwwkmircoil source accelmed copyright  pr newswire your recent history lse gkp gulf keyst lse qpp quindell ftse ukx ftse  lse iof iofina fx gbpusd uk sterlin stocks youve viewed will appear in this box letting you easily return to quotes youve seen previouslyregister now to create your own custom streaming stock watchlist nyse amex and asx quotes are delayed by at least  minutesall other quotes are delayed by at least  minutes unless otherwise stated by accessing the services available at advfn you are agreeing to be bound by advfns terms  conditions suggestion box investment warning copyright     cookie and privacy policy  advfn uk investors hub advfn italy advfn australia advfn brazil advfn canada advfn germany advfn japan advfn mexico advfn france advfn us finance manila p vus d  welcome bad login  try again username password forgotten password   helpadvfncom toll free dont have an account register now microsoft personalized ad preferences to opt out of personalized ads in this browser your browser history must allow firstparty and thirdparty cookies and you must have your browsing experience set to not delete browsing history on exit instructions for enabling cookies and configuring your browsing history may be available in your browsers settings privacy or help documentation sign in hold on… we’re sorry but this didn’t work you can’t turn off personalized ads right now because your browser is currently blocking thirdparty cookies we can help you fix this issue let’s get started depending on what browser you use open options or settings make sure that thirdparty cookies are not blocked anymore to find out how search your browser’s help revisit httpchoicemicrosoftcomoptout and then on the “personalized ads in this browser” tile click off ext about our ads to create a more customized online experience some of the ads you may receive on microsoft websites and apps are tailored to your previous activities searches and site visits youre in control and heres where you can make the advertising choice thats right for you ext where can i learn more about advertising on microsoft websites and apps microsoft partners with oath appnexus and other third party service providers to help present customized content and display advertisements on msn outlookcom and other websites and apps microsoft also delivers search ads to bing and our search syndication partners learn more about microsoft’s privacy practices here you can learn more about interestbased ads from oath and appnexus in their privacy statements oath and appnexus what choices do i have about interestbased advertising on this page you can opt out of receiving interest based advertising from microsoft you can also opt out of receiving interestbased advertising from all selfregulatory members including microsoft oath appnexus and other third party ad networks at the following sites in the us digital advertising alliance daa in europe european interactive digital advertising alliance edaa in canada ad choices digital advertising alliance of canada daac you can control interestbased advertising in windows apps by turning off the advertising id in windows settings more choices do you want personalized ads from other companies questions if you have a privacy question or a question for the chief privacy officer of microsoft please contact us by using our web form we will respond to questions within  days ext personalized ads in this browser off optout is currently unavailable please try again later control the personalized ads setting for this web browser learn more if you want microsoft to show ads that might be relevant to you click on to show “generic” ads click off ext personalized ads wherever i use my microsoft account off sign in to change optout is currently unavailable please try again later control the personalized ads setting that applies when you are signed in on any computer or device with your microsoft account including windows windows phone xbox and other devices learn more if you want microsoft to show ads that might be relevant to you click on to show “generic” ads click off if you choose “generic” ads and use a browser your choice applies to everyone when using that browser as long as you do not clear your cookies ext personalized ads in windows in your windows settings you can turn off personalized ads that appear in apps on this device you’ll still see ads but they won’t be personalized anymore if you have windows  access the charms by touching or moving your pointer to the right edge of the screen click or tap settings and then click or tap change pc settings click or tap privacy and then turn off let apps use my advertising id for experiences across apps if you have windows  click or tap the start button click or tap settings click or tap privacy and then turn off let apps use my advertising id for experiences across apps if you have a windows mobile device go to settings tap on privacy tap on advertising id and then turn off let apps use my advertising id for experiences across apps if you want to turn off personalized ads from microsoft wherever you use your microsoft account including apps on windows windows phone xbox and other devices you can do so by selecting the microsoft account option above ext legal privacy  cookies   microsoft product information management software  plytix pricing solutions product information manager product analytics tool about about us blog press contact sign in get started your product content hub manage optimize and distribute your product content from one cloud platform to get to market faster   x features pricing testimonials launch products faster eliminate the time consuming tasks that holds you back launch products x faster by enriching optimizing and distributing product content from one location crosschannel coherence over half of all shoppers research products on multiple channels before making a purchase with consistent quality product information potential customers will become loyal customers turn spreadsheets into workspace the plytix pim takes all the data you have buried in spreadsheets with smart import mapping get a workspace that lets you add text media and define custom attributes errorfree digital asset management make sure all your product and brand assets are organized and easily accessible by your whole team link images videos pdfs and other files to products without needing duplicate content  digital product catalogs create interactive download centers for your catalogs share them via public link or embed them directly onto your website catalogs are enhanced with email notifications so that you know where all your content goes be the master of your content take control of your product content and see the difference in your bottom line rich consistent content plus the efficiency provided by a pim can boost sales by   get the full feature  pricing list experience the difference other pim systems are complicated and expensive plytix offers affordable readytouse product information management software that is simple enough for entire teams to use and powerful enough to support limitless growth     i finally have one place for all of my data thats always updated and available to me no matter where i am mai johansson  mai copenhagen growth estimate price per month number of products no credit card required pay as you grow all features included unlimited users unlimited variations xml template builder digital asset management onboarding assistance available type number of products here enterprise customideal for  products need something different let’s talk all features included fixed price per month dedicated account manager integration support free onboarding helloplytixcom bernhard bangs allé   frederiksberg denmark          solutions multichannel product distribution plytix for brands plytix for retailers software product information manager product analytics tool resources what is pim pim vs dam analytics tool comparison product updates support terms and conditions plytix about us blog press career contact our site uses cookies by continuing to browse this site you are agreeing to our use of cookies more information close about  plytix pricing solutions product information manager product analytics tool about about us blog press contact sign in get started a smart product management hub for retailthat streamlines digital content and data sharing our mission   we have made it our mission to provide brands and retailers simple and affordable tools that tackle many challenges in digital product management and distribution by solving the practical challenge of organizing sourcing and sharing product content giving brands and retailers access to a whole new level of detailed ecommerce data and analytics take control of your products with plytix   our story   the idea for plytix evolved from our time at google when we were working with some of the biggest companies in the ecommerce space at the time technology allowed tracking user behaviour on individual websites but we wanted to give brands and retailers access to a whole new level of detailed data bringing them a better understanding of their products through rd party product analytics    since then plytix has evolved into an endtoend product management ecosystem where brands and retailers can organize analyze and share product content and performance in a userfriendly and efficient way without breaking the bank    our team   were a diverse international team passionate about creating extraordinary client experiences and serious about revolutionizing ecommerce we are growing rapidly and were always on the look out for smart driven people to join our team    get a closer look on  linkedin and instagram join our team  see current openings helloplytixcom bernhard bangs allé   frederiksberg denmark          solutions multichannel product distribution plytix for brands plytix for retailers software product information manager product analytics tool resources what is pim pim vs dam analytics tool comparison product updates support terms and conditions plytix about us blog press career contact our site uses cookies by continuing to browse this site you are agreeing to our use of cookies more information close contact us  plytix pricing solutions product information manager product analytics tool about about us blog press contact sign in get started wed love to talk to youdont hesitate to reach out with any questions concerns or proposals contact us you can also find us at      helloplytixcom                  bernhard bangs allé        frederiksberg     denmark   camino san antón       málaga     spain     helloplytixcom bernhard bangs allé   frederiksberg denmark           solutions multichannel product distribution plytix for brands plytix for retailers software product information manager product analytics tool resources what is pim pim vs dam analytics tool comparison product updates support terms and conditions plytix about us blog press career contact our site uses cookies by continuing to browse this site you are agreeing to our use of cookies more information close pricing  plytix pricing solutions product information manager product analytics tool about about us blog press contact sign in get started simplified pricing for better product management growth pricing about how many products are you managing price per month product information manager we base our pricing on the number of products you have not number of users or storage space estimate your cost per month using our nifty pricing calculator      give it a go try the plytix pim free for  days no credit card required all features included unlimited users what you get catalog creation management unlimited custom attributes custom product views variation handling digital asset management unlimited users xml  csv template builders data import mapping activity logs catalog print versions catalog download notifications progress tracking need a hand during implementation weve got you covered plytix will help you onboard all your product material  got a lot of skus we know that growth pricing isnt right for everyone let us know what your needs are and well set you up with a custom quote  helloplytixcom bernhard bangs allé   frederiksberg denmark          solutions multichannel product distribution plytix for brands plytix for retailers software product information manager product analytics tool resources what is pim pim vs dam analytics tool comparison product updates support terms and conditions plytix about us blog press career contact our site uses cookies by continuing to browse this site you are agreeing to our use of cookies more information close plytix  product analytics  ouch something went wrong or that page doesnt exist yet